Completed PHASE1 INTERVENTIONAL 2-arm NCT03474640

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Conditions Advanced Malignancies

Interventions Part A Part B

Updated 14 times since 2018 Last updated: Oct 2, 2024 Started: Feb 21, 2018 Primary completion: Jun 7, 2022 Completion: Jul 7, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Malignancies, this trial is completed. The trial is conducted by Shanghai Junshi Bioscience Co., Ltd. and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

14 versions recorded

Dec 2024 — Present [monthly]

Completed PHASE1

Status: Unknown → Completed
Sep 2024 — Dec 2024 [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2024 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status
Jan 2022 — Jan 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 9 earlier versions

May 2021 — Jan 2022 [monthly]

Recruiting PHASE1
Jan 2021 — May 2021 [monthly]

Recruiting PHASE1
Oct 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Mar 2020 — Oct 2020 [monthly]

Recruiting PHASE1
Aug 2019 — Mar 2020 [monthly]

Recruiting PHASE1
Apr 2019 — Aug 2019 [monthly]

Recruiting PHASE1
Feb 2019 — Apr 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE1
Apr 2018 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Junshi Bioscience Co., Ltd.
TopAlliance Biosciences

Data source: TopAlliance Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Baltimore, United States , Cleveland, United States , Detroit, United States , Houston, United States , Huntersville, United States , Miami, United States , Nashville, United States , Providence, United States , Rochester, United States and 2 more locations